These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 23216370)

  • 1. Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.
    Heuberger JA; Cohen Tervaert JM; Schepers FM; Vliegenthart AD; Rotmans JI; Daniels JM; Burggraaf J; Cohen AF
    Br J Clin Pharmacol; 2013 Jun; 75(6):1406-21. PubMed ID: 23216370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trial.
    Heuberger JAAC; Rotmans JI; Gal P; Stuurman FE; van 't Westende J; Post TE; Daniels JMA; Moerland M; van Veldhoven PLJ; de Kam ML; Ram H; de Hon O; Posthuma JJ; Burggraaf J; Cohen AF
    Lancet Haematol; 2017 Aug; 4(8):e374-e386. PubMed ID: 28669689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some empirical notes on the epo epidemic in professional cycling.
    Lodewijkx HF; Brouwer B
    Res Q Exerc Sport; 2011 Dec; 82(4):740-54. PubMed ID: 22276416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. World-class cyclists on erythropoietin.
    Heuberger JA; Cohen AF
    Br J Clin Pharmacol; 2014 Mar; 77(3):582. PubMed ID: 23772931
    [No Abstract]   [Full Text] [Related]  

  • 5. DOPING. Cyclists' favorite drug falls flat in trial.
    Enserink M
    Science; 2016 Jul; 353(6296):206-7. PubMed ID: 27418482
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of erythropoietin abuse on exercise performance.
    Sgrò P; Sansone M; Sansone A; Romanelli F; Di Luigi L
    Phys Sportsmed; 2018 Feb; 46(1):105-115. PubMed ID: 29113535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Little soldiers in their cardboard cells.
    van Breda E; Benders J; Kuipers H
    Br J Clin Pharmacol; 2014 Mar; 77(3):580-1. PubMed ID: 23772979
    [No Abstract]   [Full Text] [Related]  

  • 8. Ergogenic aids: a review of basic science, performance, side effects, and status in sports.
    Tokish JM; Kocher MS; Hawkins RJ
    Am J Sports Med; 2004 Sep; 32(6):1543-53. PubMed ID: 15310585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Condemning and condoning: Elite amateur cyclists' perspectives on drug use and professional cycling.
    Outram SM; Stewart B
    Int J Drug Policy; 2015 Jul; 26(7):682-7. PubMed ID: 25666447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity.
    Thomsen JJ; Rentsch RL; Robach P; Calbet JA; Boushel R; Rasmussen P; Juel C; Lundby C
    Eur J Appl Physiol; 2007 Nov; 101(4):481-6. PubMed ID: 17668232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of whole-blood transcriptome signature during microdose recombinant human erythropoietin (rHuEpo) administration.
    Wang G; Durussel J; Shurlock J; Mooses M; Fuku N; Bruinvels G; Pedlar C; Burden R; Murray A; Yee B; Keenan A; McClure JD; Sottas PE; Pitsiladis YP
    BMC Genomics; 2017 Nov; 18(Suppl 8):817. PubMed ID: 29143667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.
    Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):343-54. PubMed ID: 26889660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of EPO on Blood Parameters and Running Performance in Kenyan Athletes.
    Haile DW; Durussel J; Mekonen W; Ongaro N; Anjila E; Mooses M; Daskalaki E; Mooses K; McClure JD; Sutehall S; Pitsiladis YP
    Med Sci Sports Exerc; 2019 Feb; 51(2):299-307. PubMed ID: 30188362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid.
    Wilber RL
    Sports Med; 2002; 32(2):125-42. PubMed ID: 11817997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring recombinant human erythropoietin abuse among athletes.
    Citartan M; Gopinath SCB; Chen Y; Lakshmipriya T; Tang TH
    Biosens Bioelectron; 2015 Jan; 63():86-98. PubMed ID: 25058943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity and specificity of detection methods for erythropoietin doping in cyclists.
    Heuberger JAAC; van Eenoo P; Rotmans JI; Gal P; Stuurman FE; Post TE; Daniels JMA; Ram H; de Hon O; Burggraaf J; Cohen AF
    Drug Test Anal; 2019 Sep; 11(9):1290-1301. PubMed ID: 31232530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Putative effects of doping in cycling].
    Kuipers H
    Ned Tijdschr Geneeskd; 2006 Dec; 150(48):2643-5. PubMed ID: 17205940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein intake during training sessions has no effect on performance and recovery during a strenuous training camp for elite cyclists.
    Hansen M; Bangsbo J; Jensen J; Krause-Jensen M; Bibby BM; Sollie O; Hall UA; Madsen K
    J Int Soc Sports Nutr; 2016; 13():9. PubMed ID: 26949378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a caffeinated mouth-rinse on endurance cycling time-trial performance.
    Doering TM; Fell JW; Leveritt MD; Desbrow B; Shing CM
    Int J Sport Nutr Exerc Metab; 2014 Feb; 24(1):90-7. PubMed ID: 23980239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-alanine improves sprint performance in endurance cycling.
    Van Thienen R; Van Proeyen K; Vanden Eynde B; Puype J; Lefere T; Hespel P
    Med Sci Sports Exerc; 2009 Apr; 41(4):898-903. PubMed ID: 19276843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.